• Marvel Biosciences launched a non-brokered private placement of units priced at $0.15, targeting $1.5 million to $3 million gross.
• Deal size set at 10,000,000 to 20,000,000 units, each with one common share plus one warrant.
• Warrants exercise at $0.2, start 61 days post-close, expire after one year; expiry can accelerate if VWAP hits $0.25.
• Net proceeds earmarked for a phase 1 clinical trial deposit for MB-204, general and administrative costs, working capital.
• First tranche expected around Sept. 30, 2026; offering document dated Sept. 16, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609171705NEWSFILECNPR____20260917_314823_1) on September 17, 2026, and is solely responsible for the information contained therein.